Tau accumulation in Alzheimer’s disease is associated with short term clinical progression and faster rates of cognitive decline in individuals with high amyloid-β deposition. Defining an optimal threshold of tau accumulation predictive of cognitive decline remains a challenge.
Objective:
We tested the ability of regional tau PET sensitivity and specificity thresholds to predict longitudinal cognitive decline. We also tested the predictive performance of thresholds in the proposed new NIA-AA biological staging for Alzheimer’s disease where multiple levels of tau positivity are used to stage participants.
Methods:
18F-flortaucipir scans from 301 non-demented participants were processed and sampled. Four cognitive measures were assessed longitudinally. Regional standardized uptake value ratios were split into infra- and suprathreshold groups at baseline using previously derived thresholds. Survival analysis, log rank testing, and Generalized Estimation Equations assessed the relationship between the application of regional sensitivity/specificity thresholds and change in cognitive measures as well as tau threshold performance in predicting cognitive decline within the new NIA-AA biological staging.
Results:
The meta temporal region was best for predicting risk of short-term cognitive decline in suprathreshold, as compared to infrathreshold participants. When applying multiple levels of tau positivity, each subsequent level of tau identified cognitive decline at earlier timepoints.
Conclusions:
When using 18F-flortaucipir, meta temporal suprathreshold classification was associated with increased risk of cognitive decline, suggesting that abnormal tau deposition in the cortex predicts decline. Likewise, the application of multiple levels of tau clearly predicts the distinctive cognitive trajectories in the new NIA-AA biological staging framework.
VillemagneVL, BurnhamS, BourgeatP, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol2013; 12: 357–367.
2.
OssenkoppeleR, Pichet BinetteA, GrootC, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med2022; 28: 2381–2387.
3.
Strikwerda-BrownC, HobbsDA, GonneaudJ, et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol2022; 79: 975–985.
4.
SchöllM, LockhartSN, SchonhautDR, et al. PET imaging of tau deposition in the aging human brain. Neuron2016; 89: 971–982.
5.
LeuzyA, ChiotisK, LemoineL, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry2019; 24: 1112–1134.
6.
SmithR, SchollM, LeuzyA, et al. Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948. Eur J Nucl Med Mol Imaging2020; 47: 342–354.
7.
GogolaA, MinhasDS, VillemagneVL, et al. Direct comparison of the tau PET tracers (18)F-Flortaucipir and (18)F-MK-6240 in human subjects. J Nucl Med2022; 63: 108–116.
8.
JackCR, BennettDA, BlennowK, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology2016; 87: 539.
9.
JackCR, WisteHJ, WeigandSD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement2017; 13: 205–216.
10.
JackCRJr., AndrewsJS, BeachTG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement2024; doi: 10.1002/alz.13859.
11.
MishraS, GordonBA, SuY, et al. AV-PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. Neuroimage2017; 161: 171–178.
12.
OssenkoppeleR, RabinoviciGD, SmithR, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA2018; 320: 1151–1162.
13.
OssenkoppeleR, SmithR, Mattsson-CarlgrenN, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol2021; 78: 961–971.
14.
LeuzyA, PascoalTA, StrandbergO, et al. A multicenter comparison of [(18)F]flortaucipir, [(18)F]RO948, and [(18)F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur J Nucl Med Mol Imaging2021; 48: 2295–2305.
15.
BetthauserTJ, CodyKA, ZammitMD, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand (18)F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med2019; 60: 93–99.
16.
MacedoAC, TissotC, TherriaultJ, et al. The use of tau PET to stage Alzheimer disease according to the Braak staging framework. J Nucl Med2023; 64: 1171–1178.
17.
St-OngeF, ChapleauM, BreitnerJCS, et al. Tau accumulation and its spatial progression across the Alzheimer’s disease spectrum. Brain Commun2024; 6: fcae031.
18.
WeigandAJ, BangenKJ, ThomasKR, et al. Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity. Brain Commun2020; 2: fcz046.
19.
SanchezJS, BeckerJA, JacobsHIL, et al. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with positron emission tomography. Sci Transl Med2021; 13: eabc0655.
20.
StoufferKM, GrandeX, DuzelE, et al. Amidst an amygdala renaissance in Alzheimer’s disease. Brain2024; 147: 816–829.
21.
GogolaA, LoprestiBJ, TudorascuD, et al. Biostatistical estimation of tau threshold hallmarks (BETTH) algorithm for human tau PET imaging studies. J Nucl Med2023; 64: 1798–1805.
22.
MaassA, LandauS, BakerSL, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer’s disease. Neuroimage2017; 157: 448–463.
23.
BraakH and BraakE. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging1995; 16: 271–278; discussion 278-284.
24.
VillemagneVL, LeuzyA, BohorquezSS, et al. CenTauR: towards a universal scale and masks for standardizing tau imaging studies. Alzheimers Dement (Amst)2023; 15: e12454.
25.
RoweC, AmadoruS, DoreV, et al. Correlation of amyloid PET in centiloid units with neuropathological findings in Alzheimer’s disease. J Nucl Med2018; 59: 482.
26.
OkonkwoDO, PufferRC, MinhasDS, et al. [18F]FDG, [11C]PiB, and [18F]AV-1451 PET imaging of neurodegeneration in two subjects with a history of repetitive trauma and cognitive decline. Front Neurol2019; 10: 831.
27.
FischlB, van der KouweA, DestrieuxC, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex2004; 14: 11–22.
28.
ShcherbininS, SchwarzAJ, JoshiA, et al. Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer disease. J Nucl Med2016; 57: 1535–1542.
29.
BakerSL, LockhartSN, PriceJC, et al. Reference tissue–based kinetic evaluation of 18F-AV-1451 for tau imaging. J Nucl Med2017; 58: 332–338.
30.
Rivest-HénaultD, DowsonN, GreerPB, et al. Robust inverse-consistent affine CT-MR registration in MRI-assisted and MRI-alone prostate radiation therapy. Med Image Anal2015; 23: 56–69.
31.
KleinA and TourvilleJ. 101 labeled brain images and a consistent human cortical labeling protocol. Front Neurosci2012; 6: 171.
32.
HostetlerED, WaljiAM, ZengZ, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med2016; 57: 1599–1606.
33.
MarquiéM, NormandinMD, VanderburgCR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol2015; 78: 787–800.
34.
R Core Team. R: A Language and Environment for Statistical Computing. 2021.
35.
KaplanEL and MeierP. Nonparametric estimation from incomplete observations. J Am Stat Assoc1958; 53: 457–481.
36.
MantelN. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep1966; 50: 163–170.
37.
LiangK-Y and ZegerSL. Longitudinal data analysis using generalized linear models. Biometrika1986; 73: 13–22.
38.
HardinJW and HilbeJM. Generalized estimating equations. 1st ed. New York: Chapman and Hall/CRC, 2002.
39.
BrumWS, CullenNC, JanelidzeS, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases. Nat Aging2023; 3: 1079–1090.
40.
VillemagneVL, LoprestiBJ, DoréV, et al. What is T+? A Gordian knot of tracers, thresholds, and topographies. J Nucl Med2021; 62: 614.
41.
AmadoruS, DoréV, McLeanCA, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease. Alzheimers Res Ther2020; 12: 22.
42.
RafiiMS, SperlingRA, DonohueMC, et al. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer’s disease. Alzheimers Dement2023; 19: 1227–1233.
43.
ChoH, ChoiJY, HwangMS, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology2016; 87: 375–383.
44.
OssenkoppeleR, SchonhautDR, SchöllM, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain2016; 139: 1551–1567.
45.
MurrayME, Graff-RadfordNR, RossOA, et al. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol2011; 10: 785–796.
46.
ProvostK, IaccarinoL, Soleimani-MeigooniDN, et al. Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. Eur J Nucl Med Mol Imaging2021; 48: 2259–2271.
47.
FleisherAS, PontecorvoMJ, DevousMDSr, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol2020; 77: 829–839.
48.
LeuzyA, DoreV, RaketLL, et al. Harmonization of tau-PET in Alzheimer’s disease: comparison of methods to derive CenTauR units for [18F]RO948, [18F]Flortaucipir, and [18F]MK-6240. Alzheimers Dement2023; 19: e080421.
49.
MinhasD, GogolaA, LoprestiB, et al. Considerations for a universal tau PET reference region. In: Alzheimer’s Association Tau 2022 Global Conference Online, 2022, Alzheimer’s Association.
